Fritextsökning
Artiklar per år
Innehållstyper
-
VGR anmäler Millennium – hade kunnat orsaka dödsfall
Problemen var omfattande de dagar Millennium var i bruk på Södra Älvsborgs sjukhus. Nu anmäler Västra Götalandsregionen en rad händelser som innebar stora risker för patientsäkerheten.
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks approved treatment alternatives. "We can't do that on our own – our entire R&D activities are about working together with others," says the company's CEO Jens Lindberg.
-
Varningar om Millennium ignorerades
”Som att hälla flytande cement i organisationen.” Så beskriver IT-professorn Johan Magnusson det hårt kritiserade journalsystemet Millennium. Efter flera turer har nu regionen backat, men varningarna var många långt innan införandet.
-
Drug development booms in Medicon Valley
When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical companies are highlighted as a success factor. “Everyone has heard of Novo Nordisk, but these companies are unknown to people outside the industry despite being the golden vein of the life science sector,” says Anette Steenberg, CEO of the cluster organisation MVA.
-
Roche’s Genentech terminates licencing deal with Norwegian biotech
Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.
-
FHM bröt mot regler för upphandling – anmäler sig själv
Folkhälsomyndigheten kände sig ”tvingade” att utan anbudsförfarande ingå ett kontrakt som låg tio gånger över gränsen för direktupphandlingar. Nu har myndigheten valt att anmäla sig själv till Konkurrensverket för brott mot lagen om offentlig upphandling, LOU.
-
Nio förslag från branschen för bättre life science i EU
Ett enhetligt regelverk för kliniska prövningar, en både holistisk och målinriktad life science-strategi – och ett särskilt kontor inom EU-kommissionen för att koordinera life science-frågor. Så lyder några av förslagen från nordiska branschorganisationer till EU.
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What we see is a significant unmet need, so we are expecting to have quite a good welcoming in the market", says Daniel Lucas, Managing Director Nordic Countries at the American pharmaceutical giant Eli Lilly.
-
”The importance of stratification in a statistician’s August kitchen”
Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.
-
Mathias Uhlén om kemipriset: ”Största nyttan är för förståelsen av människans biologi”
Årets Nobelpris i kemi gick till forskare som lyckats bygga och förutspå proteiners märkliga struktur. ”All medicinsk forskning har intresse för det här”, säger Mathias Uhlén, hjärnan bakom Human Protein Atlas.
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the billion-selling GLP1 analogues. ‘‘Basically, I expect all the beneficial effects that they have, but not the same side effect profile,’’ company founder Dorte X Gram said in an interview with Life Science Sweden.
-
GSK pays 2.2 billion dollars to settle Zantac lawsuits
British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against the company in the U.S. that alleged its discontinued drug Zantac caused cancer.
-
Tidig operation gav bättre överlevnad i prostatacancer
Operation direkt av prostatacancer gav längre livslängd för patienterna än ett mer avvaktande tillvägagångssätt i en 30 år lång skandinavisk studie ledd från Uppsala universitet.
-
This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”
This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understanding the mechanism has changed our view of human biology and evolution, says KI Professor András Simon.
-
AstraZeneca to use American AI platform for cancer trials
In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.
-
An increasing number of people are falling ill with TBE – “Much more research is needed”
Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Överby Wernstedt is studying the processes that occur in the brain during a TBE infection and hopes to contribute to developing a treatment.
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along for much of the journey and has experienced setbacks, but also huge discoveries. “It’s amazing when you succeed,” she says.
-
Läkemedelsbolag misstänks för prissamarbete – razzior i Sverige och Danmark
Svenska Konkurrensverket och dess danska motsvarighet har genomfört tillslag mot flera företag som misstänks för otillåten samordning av prisnivåer på generiska läkemedel.
-
Anna Törner: ”Mom, do you think you’ll ever get married again?”
”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence intervals”, Anna Törner writes in a column.
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
“We should avoid surgery if we can”
Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about role models, surgery and Sweden’s strengths and weaknesses in medical research.
-
Philips får ny Sverigechef
Den nederländska koncernen Philips har rekryterat Anna Rehman Linder till ny Sverigechef.
-
Företagare föreslås ta över klubban i Lundabolaget CLS
Både ordföranden och en styrelseledamot meddelar att de lämnar det skånska företaget Clinical Laserthermia Systems. Till ny ordförande föreslås företagaren Peter Max.
BREAKING